Charles Grob, M.D. is Director of the Division of Child and Adolescent Psychiatry at Harbor-UCLA Medical Center and Professor of Psychiatry and Pediatrics at the UCLA School of Medicine. He did his undergraduate work at Oberlin College and Columbia University, and obtained a B.S. from Columbia. He received his M.D. from the State University of New York, Downstate Medical Center. Prior to his appointment at UCLA, Grob held teaching and clinical positions at the University of California at Irvine, College of Medicine, and The Johns Hopkins University School of Medicine, Departments of Psychiatry and Pediatrics. Charles conducted the first U.S. government approved psychobiological research study of MDMA, and was the principal investigator of an international research project in the Brazilian Amazon, studying the visionary plant brew, ayahuasca.
He is currently conducting an approved research investigation on the safety and efficacy of psilocybin treatment in terminally ill patients with anxiety. He is the editor of Hallucinogens: A Reader, and the co-editor (with Roger Walsh) of Higher Wisdom: Eminent Elders Explore The Continuing Impact Of Psychedelics, and he has published numerous articles on psychedelics in medical and psychiatric journals. Charles is also a founding member of the Heffter Research Institute, which is devoted to fostering and funding research on psychedelics.
During the first three hours, Professor of Psychiatry at the UCLA School of Medicine Dr. Charles Grob and Marilyn Schiltz PhD with the Institute of Noetic Sciences discussed new research with hallucinogenic substances from a medical-holistic perspective.